Jack F.M. Wetzels

28.8k total citations · 2 hit papers
394 papers, 14.3k citations indexed

About

Jack F.M. Wetzels is a scholar working on Nephrology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jack F.M. Wetzels has authored 394 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Nephrology, 82 papers in Molecular Biology and 78 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jack F.M. Wetzels's work include Renal Diseases and Glomerulopathies (156 papers), Chronic Kidney Disease and Diabetes (104 papers) and Dialysis and Renal Disease Management (51 papers). Jack F.M. Wetzels is often cited by papers focused on Renal Diseases and Glomerulopathies (156 papers), Chronic Kidney Disease and Diabetes (104 papers) and Dialysis and Renal Disease Management (51 papers). Jack F.M. Wetzels collaborates with scholars based in Netherlands, United States and Germany. Jack F.M. Wetzels's co-authors include Julia M. Hofstra, Jeroen K. Deegens, Dorine W. Swinkels, A. J. W. Branten, Jan A.J.G. van den Brand, Rosalinde Masereeuw, Bart Smeets, Andries J. Hoitsma, Henry Dijkman and Joost G.J. Hoenderop and has published in prestigious journals such as The Lancet, JAMA and Journal of Biological Chemistry.

In The Last Decade

Jack F.M. Wetzels

386 papers receiving 14.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Age and Association of Kidney Measures With Mortality and End-stage Renal Disease

2012 420 citations Jack F.M. Wetzels et al. profile →
Membranous nephropathy

2021 248 citations Pierre Ronco, Laurence H. Beck et al. Nature Reviews Disease Primers profile →

Peers

Countries citing papers authored by Jack F.M. Wetzels

Since Specialization

Citations

This map shows the geographic impact of Jack F.M. Wetzels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack F.M. Wetzels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack F.M. Wetzels more than expected).

Fields of papers citing papers by Jack F.M. Wetzels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack F.M. Wetzels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack F.M. Wetzels. The network helps show where Jack F.M. Wetzels may publish in the future.

Co-authorship network of co-authors of Jack F.M. Wetzels

This figure shows the co-authorship network connecting the top 25 collaborators of Jack F.M. Wetzels. A scholar is included among the top collaborators of Jack F.M. Wetzels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack F.M. Wetzels. Jack F.M. Wetzels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney 2024 ·Nephrology Dialysis Transplantation ·(unknown), Ben Sprangers, Alferso C Abrahams, Priyanka Koshy, Rob C.M. van Kruijsdijk, (unknown), (unknown), Michel Delforge, Josephine M. I. Vos, Jack F.M. Wetzels, Amélie Dendooven, Amaryllis H. Van Craenenbroeck	2
2	Albumin determined by bromocresol green leads to erroneous results in routine evaluation of patients with chronic kidney disease 2023 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Marith van Schrojenstein Lantman, Anne-Els van de Logt, (unknown), Marloes Langelaan, Ayşe Y. Demir, Steef Kurstjens, Armando van der Horst, Aldy W.H.M. Kuypers, (unknown), Jenny E. Kootstra‐Ros, Eline A.E. van der Hagen, M. van Oostendorp, (unknown), Christian Ramakers, (unknown), (unknown), (unknown), Marc Thelen, Jack F.M. Wetzels, Miranda van Berkel	11
3	Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan 2022 ·American Journal of Nephrology ·Steven D. Podos, Howard Trachtman, Gerald B. Appel, Andrew S. Bomback, Bradley P. Dixon, Jack F.M. Wetzels, H. Terence Cook, Samir V. Parikh, Matthew C. Pickering, (unknown), Craig B. Langman, Liz Lightstone, C. John Sperati, Erica Daina, (unknown), Kara Rice, Jane A. Thanassi, Mingjun Huang, Carla Nester, Giuseppe Remuzzi	11
4	Establishment and characterization of a novel conditionally immortalized human parietal epithelial cell line 2021 ·Experimental Cell Research ·(unknown), (unknown), (unknown), Fieke Mooren, (unknown), Bartholomeus T. van den Berge, Martijn van den Broek, Thea J. A. M. van der Velden, Lambertus P. van den Heuvel, Jack F.M. Wetzels, Michiel F. Schreuder, Johan van der Vlag, Jitske Jansen, Bart Smeets	1
5	Therapeutic trials in adult FSGS: lessons learned and the road forward 2021 ·Nature Reviews Nephrology ·An S. De Vriese, Jack F.M. Wetzels, Richard J. Glassock, Sanjeev Sethi, Fernando C. Fervenza	63
6	Membranous nephropathy breakdown → 2021 ·Nature Reviews Disease Primers ·Pierre Ronco, Laurence H. Beck, Hanna Dêbiec, Fernando C. Fervenza, Fan Fan Hou, Vivekanand Jha, Sanjeev Sethi, Allison Tong, Marina Vivarelli, Jack F.M. Wetzels	248
7	Felzartamab in Patients with Anti-Phospholipase A2 Receptor Autoantibody Positive (Anti-PLA2R+) Membranous Nephropathy (MN): Interim Results from the M-PLACE Study 2021 ·Journal of the American Society of Nephrology ·Brad H. Rovin, Sharon G. Adler, Elion Hoxha, Ben Sprangers, Rolf A.K. Stahl, Jack F.M. Wetzels, Bettina Schwamb, Rainer Boxhammer, Quynh Nguyen, (unknown), Pierre Ronco	1
8	Serum albumin measurement in nephrology: room for improvement 2020 ·Nephrology Dialysis Transplantation ·Marith van Schrojenstein Lantman, Anne-Els van de Logt, Marc Thelen, Jack F.M. Wetzels, Miranda van Berkel	10
9	Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis 2020 ·Journal of the American Society of Nephrology ·Michael L. Merchant, Michelle T. Barati, Dawn J. Caster, (unknown), (unknown), Susan Coventry, Michael E. Brier, Daniel W. Wilkey, Ming Li, Ilse M. Rood, Jeroen K. Deegens, Jack F.M. Wetzels, Christopher P. Larsen, Jonathan P. Troost, Jeffrey B. Hodgin, Laura H. Mariani, Matthias Kretzler, Jon B. Klein, Kenneth R. McLeish	26
10	NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor 2019 ·Molecular Omics ·Claire L. Boulangé, Ilse M. Rood, Joram M. Posma, John C. Lindon, Elaine Holmes, Jack F.M. Wetzels, Jeroen K. Deegens, Manuja Kaluarachchi	6
11	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab 2019 ·Clinical Pharmacokinetics ·Kioa L. Wijnsma, Rob ter Heine, Dirk Jan A. R. Moes, Saskia Langemeijer, Saskia E.M. Schols, Elena B. Volokhina, Lambertus P. van den Heuvel, Jack F.M. Wetzels, Nicole C. A. J. van de Kar, Roger J. M. Brüggemann	93
12	Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing 2019 ·Pharmaceuticals ·(unknown), Coby M. Laarakkers, Hilde P.E. Peters, Antonius E. van Herwaarden, Hans Groenewoud, Joanna IntHout, Jack F.M. Wetzels, Rachel P. L. van Swelm, Dorine W. Swinkels	7
13	Renal concentrating ability and glomerular filtration rate in lithium-treated patients. 2019 ·PubMed ·(unknown), (unknown), Moniek W.M. van de Luijtgaarden, Erwin G. Th. M. Hartong, Koen P. Grootens, Ralph Kupka, Ursula M. H. Klumpers, P.M.T. Deen, Sandrine Gaillard, Jack F.M. Wetzels	8
14	Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease 2015 ·Hypertension ·(unknown), Michiel L. Bots, Arjan D. van Zuilen, Jack F.M. Wetzels, Peter J. Blankestijn	36
15	Immunosuppressive therapy in patients with IgA nephropathy. 2015 ·Data Archiving and Networked Services (DANS) ·Harm Peters, (unknown), S. Paul Berger, Jack F.M. Wetzels	4
16	Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice? 2012 ·PubMed ·Julia M. Hofstra, Jack F.M. Wetzels	45
17	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA 2012 ·Nephrology Dialysis Transplantation ·Hilde P.E. Peters, Adam Rumjon, Sukhvinder S. Bansal, Coby M. Laarakkers, Jan A.J.G. van den Brand, Pantelis Sarafidis, Rebecca Musto, Jolanta Małyszko, Dorine W. Swinkels, Jack F.M. Wetzels, Iain C. Macdougall	23
18	High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy 2011 ·Nephrology Dialysis Transplantation ·Hilde P.E. Peters, Femke Waanders, Esther Meijer, Jan A.J.G. van den Brand, E. J. Steenbergen, Harry van Goor, Jack F.M. Wetzels	59
19	Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy 1994 ·Diabetologia ·L.D. Elving, Jack F.M. Wetzels, Henk J.J. van Lier, E. de Nobel, Jo H. M. Berden	40
20	Role of calcium and related mechanisms in ischemic tubular epithelial injury 1992 ·Nefrología ·Thomas J. Burke, Andreas Kribben, Jack F.M. Wetzels, Luís Yu, Eric Wieder, Robert W. Schrier	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact